LAUSR

154 Background: Two double regimens, CAPEOX (CLASSIC trial) and docetaxel/S-1 (JACCRO GC-07), were standard treatment for curatively resected gastric cancer (GC) in Asia. However, the outcome of double regimens as postoperative adjuvant treatment remains unsatisfactory and the efficacy between oxaliplatin-based or taxane-based doublets is unknown. This study aimed to investigate if triplet improve survival compared with doublets and difference between oxaliplatin-based or taxane-based doublets. Methods: We found the patients with gastric cancer who received FOLFOX or POF or TF as adjuvant chemotherapy after curatively resection between 2002 and 2015 from our hospital. The POF consisted of a three-hour infusion of paclitaxel 135 mg/m2, followed by FOLFOX omitted 5-Fu bolus. The TF is a substitution of paclitaxel 135 mg/m2 for oxaliplatin of FOLFOX. We checked the overall survival rate and the frequency of adverse reaction among the three groups. Results: We retrospectively studied 275 patients (POF 26, FOLFOX 172, TF 67). One, two, and three years OS rate were shown in table. POF was the worst survival among three regimens (p = 0.04). The patients with POF were shown more grade ¾ toxicity than two doublets. The patients with TF was more grade ¾ neutropenia, FOLFOX was more grade ¾ neuropathy. Conclusions: FOLFOX and TF which were similar in term of survival were recommended as adjuvant chemotherapy after curatively resection in the patients with gastric cancer. POF was less likely to improved survival than two doublets, which was not recommended. [Table: see text]